世茂(00813.HK)續挫8%創逾四年半低 遭匯豐看淡
世茂集團(00813.HK)上週五發聲明闢謠未有逾期或延期償付事項,澄清與陸家嘴信託合作正常。然而,匯豐研究最新給予世茂「減持」評級看8.6元。該股四連跌,今天高低見9.7元/8.82元(逾四半年半低),半日收8.87,續挫8.2%,半日成交2,558萬股(已超過昨天全日成交量2,319萬股)。
獲匯豐研究維持「買入」評級削價至21.9元的世茂服務(00873.HK)也四連跌,今早股價反覆跌破今年1月所創上市低位11.42元,高低見11.8元/10.62元,半日收10.66元,續挫8.9%,半日成交988萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.